Helixgate

Helixgate

Uncategorized

MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J

Published

on

J&J will hand over the rights to bota-vec for $25 million upfront, clearing MeiraGTx to seek regulatory approvals in the U.S. and EU in 2027.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Merck’s Welireg combo fails in first-line kidney cancer

Published

on

Adding Merck’s Welireg to an existing Keytruda regimen didn’t lead to a significant improvement in newly diagnosed patients with advanced kidney cancer, Merck announced on Tuesday.

The results mark a setback …

Continue Reading

Uncategorized

Merck’s fast-ascending kidney cancer drug hits a setback

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Read More

Published

on

Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.

Read More

Continue Reading

Uncategorized

UnitedHealth breaks down how it plans to spend $1.5B on AI

UnitedHealth breaks down how it plans to spend $1.5B on AI

Published

on

UnitedHealth Group said Tuesday it’s on track to invest $1.5 billion in artificial intelligence this year, both to improve its own operations and provide products to other insurers and healthcare providers.

The healthcare giant is …​ ​Read More

Continue Reading
Advertisement

Trending